Arvinas vs Arrowhead Pharmaceuticals
ARVN and ARWR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARVN and ARWR compare
Arrowhead Pharmaceuticals is the larger company, worth 16 times as much as Arvinas ($8.5B against $514M).
Arrowhead Pharmaceuticals grew revenue faster over the last twelve months (16.8% versus −15.0% for Arvinas).
Arvinas keeps more of each dollar of sales as profit, with a net margin of 2.9% compared with −47.8% at Arrowhead Pharmaceuticals.
Arvinas scores higher on the StockData Score (8 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARVN | ARWR |
|---|---|---|
| Size and price | ||
| Market cap | $514M | $8.5B |
| Share price | $7.86 | $59.90 |
| Change, 1 year | −18.0% | 48.7% |
| Change, 5 years | −91.4% | −25.8% |
| Beta (5Y) | 1.37 | 1.73 |
| Employees | 246 | 711 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 49.1× | – |
| P/S | 1.6× (better) | 12.6× |
| P/B | 0.9× (better) | 18.2× |
| FCF yield | −40.6% | −0.89% (better) |
| Fair value | – | $32.22 |
| Margin of safety | – | −85.9% |
| Growth | ||
| Revenue growth (TTM) | −15.0% | 16.8% (better) |
| Revenue growth, 5Y average | 58.9% (better) | 56.6% |
| Profitability | ||
| Operating margin | −5.7% (better) | −33.8% |
| Net margin | 2.9% (better) | −47.8% |
| FCF margin | −65.9% | −11.2% (better) |
| Return on equity | 1.6% (better) | −64.8% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −2.4× |
| Current ratio | 7.91 (better) | 5.90 |
| Altman Z-score | 1.01 | 2.56 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.0% | 84.6% |
| Held by insiders | 7.8% | 4.0% |
| Insider net buying, 12 months | −$1.2M (better) | −$37.3M |
| Short interest, % of float | 8.9% | 7.9% |
Go deeper
- ARVN stock overview
- ARVN income statement
- ARVN valuation and score
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.